Compare Regeneron Pharmaceuticals Inc (REGN) vs Vanguard Global ex-US Real Estate Index Fd ETF (VNQI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Regeneron Pharmaceuticals Inc trades at $808.33 (market cap $83.43B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $44.53. The key difference: Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Vanguard Global ex-US Real Estate Index Fd ETF pays none, and Regeneron Pharmaceuticals Inc is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| REGN | VNQI | |
|---|---|---|
Market Cap | $83.43B | — |
Sector | Health | — |
52-Week High | $852.03 | $50.76 |
52-Week Low | $555.51 | $43.26 |
Enterprise Value | $78.14B | — |
Dividend Yield | 0.46% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $44.95, down 0.71% with a bearish technical signal. The ETF focuses on international real estate across 30+ countries, offering a higher dividend yield than domestic peers but showing lower recent returns. Moving averages indicate selling pressure while oscillators remain neutral. Recent news highlights institutional selling and comparisons with competing real estate ETFs.
The outlook remains cautious due to technical weakness and international real estate market volatility. Investment opportunity lies in global diversification and attractive dividend yield, but risks include currency exposure and underperformance versus U.S. real estate. The bearish technical setup suggests near-term pressure despite neutral fundamental positioning.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About Vanguard Global ex-US Real Estate Index Fd ETF
The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →
